COVID-19: Siemens assay outperforms antibody tests from competitors
In a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 409 entries.
Entries by Thomas Gabrielczyk
AMR: Big Pharma sets up US$1bn Fund
10th July 2020 in News /by Thomas GabrielczykAfter leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).
VarmX bags 32m in Series B round
9th July 2020 in News /by Thomas GabrielczykLeiden-based coagulant developer VarmX NV has closed a 32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.
APEIRON Biologics licences MaxCytes electroporation platform
8th July 2020 in News /by Thomas GabrielczykViennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcytes electroporation platform for APN401 development.
Immatics launches US$250m Nasdaq-IPO
7th July 2020 in News /by Thomas GabrielczykAfter closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq.
New insulin fomulation allows faster blood sugar management
1st July 2020 in News /by Thomas GabrielczykA new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes.
COVID-19: Lopinavir-ritonavir failed
1st July 2020 in News /by Thomas GabrielczykData from the UKs RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients.
EC pledges 4.9bn to grant access to medicines
30th June 2020 in News /by Thomas GabrielczykUnder the Coronavirus Global Response Framework, the European Commission is allocating further 4.9bn to assure access to COVID-19 countermeasures for poor countries.
BioGeneration Ventures closes BGV IV Fund at 105m
24th June 2020 in News /by Thomas GabrielczykBioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at 105m.
LSP leads 11m Series A round in OneProject
24th June 2020 in News /by Thomas GabrielczykOneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an 11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.